首页 › 肝癌（肝细胞癌） › 得克萨斯州 › Houston
Houston TX 肝癌（肝细胞癌）临床试验
31项针对 肝癌（肝细胞癌）的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of ZW251 in Participants With Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
招募中1/2 期
- Research Facility, Houston
National Liver Cancer Screening Trial
招募中4 期
- Baylor College of Medicine, Houston
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- The University of Texas Md Anderson Cancer Center, Houston
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
招募中1/2 期
- M D Anderson Cancer Center, Houston
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
招募中3 期
- Research Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
招募中1/2 期
- Research Site, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
招募中1 期
- M D Anderson Cancer Center, Houston
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
招募中1 期
- Clinical Trial Site, Houston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
招募中
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
招募中1 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
招募中2 期
- M D Anderson Cancer Center, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
招募中
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
招募中2 期
- USA12-0, Houston
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
招募中观察性研究欢迎健康志愿者
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
招募中1/2 期
- MD Anderson Cancer Center, Houston
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
招募中2 期
- Houston Methodist Hospital Cancer Center, Houston
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
招募中1 期
- Oncology Consultants, Houston
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
招募中2 期
- Baylor College of Medicine, Houston
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
招募中2 期
- Houston Methodist Neal Cancer Center, Houston
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
招募中1 期
- Houston Methodist Hospital, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Houston
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
招募中4 期
- Houston Methodist Research Institute, Houston
其他城市的 肝癌（肝细胞癌）试验
- New York City, NY24 项研究
- Dallas, TX19 项研究
- Los Angeles, CA19 项研究
- Boston, MA18 项研究
- Cleveland, OH18 项研究
- Chicago, IL16 项研究
- Philadelphia, PA16 项研究
- Pittsburgh, PA15 项研究
- San Francisco, CA14 项研究
- Orange, CA14 项研究
- Jacksonville, FL14 项研究
- San Antonio, TX13 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）121 项研究
- 转移性癌症104 项研究
- 结直肠癌102 项研究
- 卵巢癌89 项研究
- 急性髓系白血病85 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌61 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。